Ocugen
June 16, 2025
Company Presentation

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.

Company HQ City:
Malvern
Company HQ State:
PA
Company HQ Country:
United States
Year Founded:
2013
Lead Product in Development:
OCU-400
CEO
Dr. Shankar Musunuri
Development Phase of Lead Product
Phase III
Exchange
NASDAQ
Ticker
OCGN
When you expect your next catalyst update?
Initiate OCU410ST Phase 2/3 pivotal confirmatory clinical trial
What is your next catalyst (value inflection) update?
mid-2025
Primary Speaker